Ian Matthew Allen MD MPH

PubMed

• 27 citations
  Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018
  Gabriel E. Molina, Leyre Zubiri, Justine V. Cohen, Sienna Durbin, Laura A. Petrillo
  The Oncologist. 2021-06-01
• 18 citations
  Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting
  Sienna Durbin, Leyre Zubiri, Andrzej Niemierko, Aditya Bardia, Ryan J. Sullivan
  The Oncologist. 2021-01-01
• 12 citations
  Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective...
  Gabriel E. Molina, Ian M. Allen, Michael S. Hughes, Leyre Zubiri, Hang Lee
  Journal of the American Academy of Dermatology. 2020-03-01

Journal Articles

• Vitamin C Supplementation in Pregnancy--Does it Decrease Rates of Preterm Birth? A Systematic Review  
  Swaney P, Allen IM, and Thorp J, Am J Perinatol, 1/1/2014
• Cancer Screening Rates in Individuals with Different Life Expectancies  
  Royce TJ, Hendrix LH, Stokes WA, Allen IM, and Chen RC, JAMA Internal Medicine, 1/1/2014
• Trends in Use of Postprostatectomy Therapies for Patients with Prostate Cancer: a Surveillance, Epidemiology, and End Results Medicare Analysis  
  Sheets NC, Hendrix LH, Allen IM, and Chen RC, Cancer, 1/1/2013

Books/Book Chapters

• House staff Manual Department of Internal Medicine Massachusetts General Hospital 
  Chapter: Section of Hematology and Oncology 
  Allen IM and Betof AHarvard Medical School2016

Abstracts/Posters

• Factors Associated with Severity of Immune Checkpoint Inhibitor-related Gastroenterocolitis in Inpatients
  Hughes MS, Zheng H, Zubiri L, Molina GE, Chen ST, Mooradian MJ, Allen IM, Reynolds KL, and Dougan ML, ASCO-SITC Clinical Immuno-Oncology Symposium, 1/1/2019
• Rates of Influenza Vaccination Among Patients Receiving Immune Checkpoint Inhibitors (ICI) Who Were Hospitalized for Severe Immune-Related Adverse Events (irAE).
  Allen IM, Murciano-Goroff YR, Hughes MD, Durbin S, Klauer MJ, Chu JN, Cohen JV, Mansour M, Bardia A, and Reynolds KL, American Society of Clinical Oncology Annual Meeting, 1/1/2019
• Clinical Outcomes of Patients with Stage IV Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
  Durbin S, Zubiri L, Petrillo L, Bardia A, McEwen C, Mulvey T, Allen IM, Lawrence D, Cohen JV, Hochberg E, Ryan D, and Reynolds K, American Society of Clinical Oncology Annual Meeting, 1/1/2019
• Cost of Inpatient Admissions for Immune-Related Adverse Effects from Immune Checkpoint Inhibitor Therapy: A Single Center Experience.
  Chu JN, Choi JG, Ostvar S, Cohen JV, Allen IM, Dougan ML, Villani AC, Thomas M, Nasrallah M, Guidon A, Chen ST, Schoenfeld S, Sise M, Leaf R, Neilan TG, Faje A, Sulliv..., American Society of Clinical Oncology Annual Meeting, 1/1/2018
• Prostate-Specific Antigen (PSA) Screening in The United States: Patterns of Use and PSA Outcomes in Screened vs. Unscreened Men.
  Allen IM, Hendrix LH, Royce TJ, Stokes WA, Chen RC, American Society of Clinical Oncology Annual Conference, 1/1/2012
• Racial Differences In Delay Of Treatment For Localized Prostate Cancer (Cap), A PopulationBased Study.
  Stokes WA, Hendrix LH, Royce TJ, Allen IM, Godley PA, Wang AZ, C and hen RC, American Society of Clinical Oncology Annual Conference, 1/1/2012
• Control of Cardiovascular Risk Factors in Cancer Survivors Compared to Non-Cancer Controls, Measured Outcomes from a Population-Based Study.
  Stokes WA, Hendrix LH, Royce TJ, Allen IM, and Chen RC, American Society for Radiation Oncology Annual Meeting, 1/1/2012
• Prognostic Implications of Co-Occurring Dermatologic and Gastrointestinal Toxicity from Immune Checkpoint Inhibition Therapy for Advanced Malignancies.
  Allen IM, Molina GE, Hughes MS, Zubiri L, Lee H, Mooradian MJ, Reynolds KL, Dougan ML, and Chen ST, World Congress of Dermatology
• Join now to see all

Lectures

• Flu vaccination rate of patients with severe immune-related adverse events. 
  2019 ASCO Annual Meeting - 6/1/2019